Search PubMed⌕ Search

Biomedical subjects

R Jemmerson

Publications and source records attributed to R Jemmerson.

At least 55 records · Page 3Linked to original sources

Antigenicity and native structure of globular proteins: low frequency of peptide reactive antibodies.

Recent reports that peptides can frequently mimic epitopes on globular proteins are inconsistent with early studies demonstrating that antibodies to native globular proteins generally do not bind peptides. This discrepancy could result from current confusion of two different populations of antibodies in antisera: one reacting with peptides and denatured protein and the other reacting only with the native protein. To test this possibility, several hundred monoclonal antibodies to rat cytochrome c were examined by ELISA for binding the intact protein and cyanogen bromide-cleaved peptides. Inhibition by soluble native cytochrome c identified which antibodies were specific for the native protein. The vast majority of these antibodies did not bind the peptides, whereas most of the antibodies specific for denatured forms did bind them. The results are consistent with the idea that antibodies to denatured antigen are readily detected in solid-phase assays, where some antigen molecules denature as they attach to microtiter plates, and show that these antibodies are generally the ones that react with peptides. Thus, reevaluation of data suggesting that anti-native globular protein antibodies bind peptides is warranted.

Amino Acid Sequence↗

A hidden antigenic determinant on membrane-bound human placental alkaline phosphatase.

Two sets of monoclonal antibodies (mAbs) specific for human placental alkaline phosphatase (PLAP) were compared. One set of four mAbs was generated against solubilized and purified PLAP; the other set of seven mAbs was generated against the malignant cell line Hela TCRC-1 in which PLAP is an ectopically synthesized membrane-bound enzyme. Double immunodiffusion and competitive enzyme-linked immunosorbent assays were used to examine the relative spatial arrangement of the antigenic determinants to which each of the eleven mAbs binds. Significant differences in immunoreactivity of the antibodies were demonstrated. The mAbs to the solubilized and purified enzyme bound in either of two regions of the molecule. By contrast, all of the mAbs to PLAP as presented on the tumor cell surface bound in only one of these two regions. One of the major antigenic determinants on the solubilized enzyme is apparently unavailable for recognition by immunoreactive cells during immunization with whole cells. Furthermore, when mAbs are generated to this region using purified PLAP as the immunogen, they do not recognize membrane-bound PLAP. The 'hidden' determinant can be exposed in vitro after partial solubilization using butanol to extract the enzyme from HeLa TCRC-1 cells and subsequent treatment with 0.5% Nonidet P-40 detergent. The results of this study have implications for the potential use of mAbs in studies of other cell surface antigens and in tumor immunolocalization and drug targeting.

Alkaline Phosphatase↗

Monoclonal antibodies to different epitopes on a cell-surface enzyme, human placental alkaline phosphatase, effect different patterns of labeling with protein A-colloidal gold.

Two monoclonal antibodies (mAbs) to different epitopes on human placental alkaline phosphatase (PLAP), both of the immunoglobulin G2a heavy-chain class and having similar affinities for PLAP, were compared for their ability to label the enzyme on the HeLa cell surface. In one type of experiment employing [125I]-labeled mAbs, the results demonstrated quantitative differences in binding of the mAbs to the cells. At saturating levels, the number of molecules of mAb E5 bound to the cells was almost eight times the number of mAb B10 molecules bound. In another type of experiment, mAbs were indirectly visualized on the cell surface using protein A tagged with colloidal gold particles in transmission electron microscopy. Only one of the antibodies (E5) displayed a clustered distribution of PLAP that previously had been observed with rabbit polyclonal antibodies and goat anti-rabbit IgG-labeled gold (J Histochem Cytochem 33:1227, 1985). The other antibody (B10) showed less frequent and more scattered labeling; three to four times more gold particles were visualized in each cluster on cells bound by mAb E5 compared to cells bound by B10. These results are consistent with the idea that not all epitopes on a membrane-bound antigen may be equally accessible for antibody binding. Even identical epitopes on different PLAP molecules are not equally hindered by other membrane components, since at least some of the PLAP molecules are labeled by the more sterically hindered mAb B10. Quantification of the number of gold particles employing the more abundantly bound mAb E5 provides an average estimate of seven to eight molecules of PLAP in each cluster. Because of inefficiencies in labeling, however, this value is probably lower than the real number.

Alkaline Phosphatase↗

Immunoelectron microscopic analysis of the binding of monoclonal antibodies to molecular variants of human placental alkaline phosphatase.

Three monoclonal antibodies with distinct antigenic specificities were examined by electron microscopy for their binding to three common genetic variants (SS, FS, and FF) of human placental alkaline phosphatase. In the reaction with the monoclonal antibody H5, all three variants of human placental alkaline phosphatase preferentially formed circular immune complexes composed of two antibodies and two enzyme molecules. In separate reactions with the F11 and B2 monoclonal antibodies, the SS variant formed circular complexes and the FS variant formed Y-shaped complexes composed of one antibody and two enzyme molecules, whereas the FF variant scarcely reacted. These results confirm immunochemical data showing that H5 binds to both S and F subunits with similar affinities, whereas F11 and B2 bind the S subunit with markedly higher affinity than they do the F subunit. Furthermore, the formation of circular complexes in the reaction of the mixture of the two antibodies, F11 and B2, with FS molecules suggests that these two antibodies bind to different sites on the S subunit. Therefore, the F and S subunits differ from one another at more than one site. This is the first indication that alleles of human placental alkaline phosphatase may result from more than just single point mutations in the gene encoding them.

Alkaline Phosphatase↗

Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes.

A monoclonal antibody bound to a protein antigen decreases the rate of proteolytic cleavage of the antigen, having the greatest effect on those regions involved in antibody contact. Thus, an epitope can be identified by the ability of the antibody to protect one region of the antigen more than others from proteolysis. By means of this approach, two distinct epitopes, both conformationally well-ordered, were characterized on horse cytochrome c.

Animals↗

Monoclonal antibodies block the bromelain-mediated release of human placental alkaline phosphatase from cultured cancer cells.

Certain monoclonal antibodies (mAbs) to human placental alkaline phosphatase (PLAP) block bromelain cleavage of a 2-kDa segment from each of the two polypeptide chains of PLAP. These mAbs also prevent the release of PLAP from cultured cancer cell surfaces by bromelain. Such proteolysis-blocking mAbs serve as tools to specifically modify the molecular topography of cell surfaces by protease treatment.

Alkaline Phosphatase↗

Analysis of an evolutionarily conserved antigenic site on mammalian cytochrome c using synthetic peptides.

Two synthetic peptides inclusive of the NH2-terminal N-acetyl-Gly-Asp-Val-Glu tetrapeptide of mammalian cytochrome c (cyt c) were used in this study to address the question of whether mammals can respond immunologically to an evolutionarily conserved region of a protein. These peptides were assessed for their capacity (i) to act as immunogens for the production of anti-self cyt c antisera and (ii) to bind rabbit anti-rodent cyt c antibody. The findings from these studies indicate the existence of an immunogenic determinant in an evolutionarily conserved region of cyt c that contains residues 1-4. This determinant can induce anti-self cyt c antibodies whether presented as a peptide on a carrier protein or in the context of the intact molecule as polymerized mammalian cyt c.

Amino Acid Sequence↗

Clustered distribution of human placental alkaline phosphatase on the surface of both placental and cancer cells. Electron microscopic observations using gold-labeled antibodies.

The cell-surface distribution of human placental alkaline phosphatase (PLAP) on cultured cancer cells, A431 and HeLa TCRC-1, and on normal syncytial cells of placental tissue was examined in immunoelectron transmission microscopy using the gold-labeling technique. Chemically fixed cells were reacted with affinity-purified rabbit polyclonal antibodies to PLAP, and the antibodies were visualized using gold particles tagged with goat antirabbit IgG. On all cells PLAP was observed in clusters distributed throughout the membrane surface, including microvilli, but it was not expressed in desmosomes or along other dense regions on the membrane. Previous histochemical and immunochemical techniques failed to demonstrate clusters. The results show that (1) the gold-labeling technique allows a more precise localization of PLAP on the cell surface than previously employed methods, and (2) the distribution of the enzyme is the same on cultured cancer cells and on normal placental syncytial cells. The clustered distribution of PLAP is thus a general phenomenon and is probably influenced by the physiological function of the enzyme, which has yet to be defined.

Alkaline Phosphatase↗

Evidence for homology of normal and neoplastic human placental alkaline phosphatases as determined by monoclonal antibodies to the cancer-associated enzyme.

The HeLa TCRC-1 human adenocarcinoma cell line expresses a form of alkaline phosphatase that is similar to the common S-variant of placental alkaline phosphatase (PLAP) on the basis of electrophoretic mobility, catalytic properties, and reactivity with polyclonal antibodies. More sensitive probes of changes in protein structure than polyclonal antibodies are monoclonal antibodies (MAbs) which recognize individual antigenic sites on molecules. Therefore, we produced MAbs to HeLa TCRC-1 cells and selected those which bound to the alkaline phosphatase expressed by the cancer cells. Seven MAbs were obtained and characterized by (a) fine specificity analysis using allelic variants of PLAP and other human alkaline phosphatase isozymes, (b) immunoglobulin isotype, and (c) relative binding affinities to PLAP from two sources, placental tissue and HeLa TCRC-1 cells. The seven MAbs bind the enzymes from both sources with equal affinity indicating a high degree of structural homology if not identity between the normal S-variant of PLAP and its cancer-associated counterpart. We note that most of the MAbs to cancer cell surface-bound PLAP express either Ig (immunoglobulin) G2a or IgG2b heavy-chain isotypes, a higher incidence of these classes of IgG than has been observed with the purified and soluble PLAP immunogen which yields MAbs predominantly of the IgG1 isotype. Finally, some of these antibodies, like the ones prepared from purified PLAP, recognize differences between allelic variants.

Adenocarcinoma↗

Characterization of the placental alkaline phosphatase-like (Nagao) isozyme on the surface of A431 human epidermoid carcinoma cells.

A431 human epidermoid carcinoma cells monophenotypically express the placental alkaline phosphatase (PLAP)-like enzyme shown by its catalytic and antigenic characteristics, properties which are shared by the Nagao isozyme. More specifically, it is L-leucine sensitive just as is the rare placental D-variant of PLAP and the testicular heat-stable enzyme. Collectively, these are all referred to as PLAP-like enzymes. The enzyme was localized to the surface of the plasma membrane since it was released in an active form by bromelain treatment of cells. The number of molecules per A431 cell was estimated by radioimmunoassay at 7.5 X 10(5), a value significantly higher than that observed for HeLa TCRC-1 cells (5 X 10(4) which express the S-variant of PLAP, also referred to as the Regan isozyme. The quantity of the enzyme was increased significantly (10-fold) by treating the cells with modulating agents including sodium butyrate, prednisolone, and hyperosmolar sodium chloride. The identification of a cell line such as A431 with enhanced expression in the amount of the PLAP-like enzyme and which can be further enhanced by modulating agents will facilitate studies of the differences and the similarities between this protein and other variants of PLAP. The A431 cell line now takes its place with other cell lines which are phenotypically restricted in their expression of alkaline phosphatase. Finally, the A431 cell line is also shown here to be a suitable model system for in vivo tumor studies such as immunolocalization.

Alkaline Phosphatase↗

Monoclonal antibodies block the trypsin cleavage site on human placental alkaline phosphatase.

Three of eleven monoclonal antibodies (mAbs) to human placental alkaline phosphatase (PLAP) were shown to block cleavage by trypsin at the only proteolytically sensitive site on the native molecule. These results illustrate the potential importance of using mAbs to restrict proteolysis of proteins, in general, and serve as a novel means to identify the relative locations of antigenic determinants.

Alkaline Phosphatase↗

Tumor immunolocalization using monoclonal antibodies which bind placental alkaline phosphatase.

Increased levels of PLAP in the serum of patients with certain types of cancer, particularly ovarian cancer and seminoma, indicate that PLAP may be a useful marker for detection of those tumors. Our goal was to further examine the usefulness of PLAP as a tumor marker by investigating the possibility that monoclonal antibodies binding PLAP may be useful for detection of the growth and metastasis of tumors which express the enzyme. Thus, we developed an experimental system where both a PLAP- positive and PLAP- negative tumor were grown in nude mice. The mice were then injected with radioactively-labeled F(ab)'2 fragments of a monoclonal antibody. The results are in accord with those of others and indicate that the monoclonal antibody localized in the PLAP-positive tumor 10 times or more often than it localized in the PLAP-negative tumor or in normal mouse tissues. Therefore, PLAP would appear to be a useful marker for the immunodetection of certain tumors in humans by external scintigraphy. PLAP may similarly be effective as a target for the delivery of toxic reagents to tumor cells in vivo using drugs conjugated to PLAP-specific monoclonal antibodies.

Alkaline Phosphatase↗

Topographic antigenic determinants on cytochrome c. Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome.

Seven populations of site-specific antibodies were isolated from each of three sera of rabbits immunized against glutaraldehyde-polymerized horse cytochrome c. The antibodies were separated using an immunoadsorption scheme which employed the following cytochromes c: horse, beef, guanaco, rabbit, mouse testicular, pigeon, and the cyanogen-bromide cleaved fragment of the rabbit protein containing residues 1 to 65. The monovalent, antigen-binding fragments of the antibodies (Fab') gave 1:1 stoichiometries with native horse cytochrome c in fluorescence quenching assays. Cross-reactivities with heterologous cytochromes c using fluorescence quenching and a modified Farr assay demonstrated that the antigenic determinants are situated around residues 44, 60, and 89/92, four of the six amino acid sequence positions where horse and rabbit cytochromes c differ. The remaining two differences occur at residues 47 and 62. The apparent lack of immunogenicity of these two substitutions may result from the presence of the more immunogenic residues 44 and 60 nearby. Of the seven antibody populations isolated, four were shown to bind in the region of residues 89 and 92. Since several cytochromes c have amino acid sequence differences from the horse protein at either of these two residue positions, it was possible to fractionate the antibodies directed against this complex site on the basis of subtle specificity differences between them. Two antibody populations bind in the region of residue 44. One of these is specific for proline at that position, while the other antibody population also binds to cytochrome c containing glutamic acid at position 44. The remaining antibody population binds in the region of the lysine residue at position 60. Each of the seven site-specific antibody populations binds effectively to any cytochrome c having a suitable amino acid sequence in the antigenic determinant regardless of any residue differences from the immunogen outside of that area. It was also demonstrated that these seven antibody populations represent the totality of the antibodies elicited in rabbits against horse cytochrome c, since the immunoadsorbants bound all the antibodies specific for the native protein. Furthermore, the rabbit antisera contained no other antibody population that could bind to the conformationally disturbed, cyanogen bromide-cleaved fragment of horse cytochrome c containing residues 1 to 65, making it appear that there were no antibodies elicited against a "processed" form of cytochrome c.

Animals↗

Specificity of the antibody response of rabbits to a self-antigen.

The demonstration that the antigenic determinants on rabbit cytochrome c that elicit antibodies in rabbits occur in regions of variability among mammalian cytochromes c suggests the existence of an evolutionary process which eliminates genetic specificities for self-determinants.

Amino Acid Sequence↗